Nun der Einstieg?
Seite 5 von 5 Neuester Beitrag: 25.04.21 02:38 | ||||
Eröffnet am: | 15.11.09 20:12 | von: makumba | Anzahl Beiträge: | 108 |
Neuester Beitrag: | 25.04.21 02:38 | von: Monikalumsa | Leser gesamt: | 23.261 |
Forum: | Hot-Stocks | Leser heute: | 11 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | 3 | 4 | > |
Warum bist du denn raus bei den Aussichten?
Die haben 3 Medikamente in der Pipeline mit eines bereits mit Zulassung in Indien. Die Bewertung ist im Vergleich zu Coherus lachhaft. Da ist Luft bis zu 30-50 USD.
Lies Dir mal Boards in USA durch. Ich würde da an Deiner Stelle wieder rein gehen.
Der Markt der Biosimilars ist erst gerade am entstehen. Es wird viel Konkurrenz geben, und der Markt wird geteilt werden. Da ist für alle Platz.
Habe meine Formycons für Epirus hergegeben..in USA ist da einfach mehr drin.
Combined companies' product pipeline targets reference biologics with sales of $29 billion in 2014
Pipeline expanded to include biosimilars to Soliris®, STELARA® and SIMPONI®
Capabilities enhanced to accelerate product development and optimize quality and yields
BOSTON, Sept. 09, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal antibodies (mAbs), today announced an agreement for the acquisition of Bioceros Holding B.V., enabling EPIRUS to expand its biosimilar pipeline and vertically integrate product development capabilities.
Bioceros is a privately-held, Netherlands-based biopharmaceutical R&D company focused on the development of mAbs and generation of GMP-ready cell lines. Over the past decade, Bioceros has developed numerous biosimilar cell lines from its proprietary, well-characterized CHO platform (CHOBC®)i. Bioceros' staff of scientists, fully-equipped labs and bioreactor capabilities have been designed for the development of mAbs and protein therapeutics, with a focus on biosimilars.
......On July 25, 2016, the Company filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Massachusetts (the “Bankruptcy Court”). As a result of this filing, a Chapter 7 trustee will be appointed by the Bankruptcy Court and will assume control of the Company. The assets of the Company will be liquidated and claims paid in accordance with the Code........